MRI Health Risk Lawyer Interviews

Boston, MA Patients who have had a gadolinium-based MRI contrast agent may have developed Nephrogenic Systemic Fibrosis (NSF) without realizing it. Some may be misdiagnosed with another condition, while others may not realize the full extent of the side effects. In this second part of a two-part series, John Dalimonte, partner at Karon & Dalimonte, discusses the potential for misdiagnosis, litigation against the makers of gadolinium-based dyes and how patients can specifically request a test for an NSF diagnosis.

Boston, MA Patients who have been diagnosed with Nephrogenic Systemic Fibrosis (NSF) know how devastating the disease can be, but many don't know what causes it or how to treat it. In this two-part series, we interview John Dalimonte, partner at Karon & Dalimonte, about MRI contrast agent side effects, causes of NSF and how patients often end up misdiagnosed.

San Francisco, CA At the nation's first Nephrogenic Systemic Fibrosis (NSF) trial in January, attorney Larry Gornick intends to prove that Bayer Healthcare Pharmaceuticals, Inc., the maker of Magnevist, could have made a safer and more stable product but chose not to bring it the US purely for financial reasons.

San Francisco, CA Attorney Debra DeCarli represents clients who have been stricken with Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD), an incurable disease associated with MRI Health Risks. DeCarli is mainly focused on warning people at risk of developing NSF/NFD via gadolinium-based contrast agent used during an MRI or MRA, particularly dialysis patients, or people with any type of kidney impairment.